Reunion Neuroscience will be advancing its psychedelic therapy RE104 to a Phase III trial in post-partum depression (PPD) in ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

As antimicrobial resistance (AMR) escalates and chronic viral infections like human immunodeficiency virus (HIV) and herpes ...

Aligos has initiated dosing in the Phase II B-SUPREME trial of its ALG-000184 in people with chronic hepatitis B virus (HBV) ...

NHS England is set to offer expedited access to the trial for BioNTech’s new cancer vaccine, BNT113-01, for individuals with ...

The Phase II STARLIGHT study (NCT05417126) found that a single intravitreal injection of gene-agnostic MCO-010 in six ...

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome ...

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.